Skip to NavigationSkip to content

India to go ahead with human trials of COVID-19 vaccine in July

Published on 30/06/20 at 11:37am
Photo by Senior Airman Areca Wilson

A trial of a new Indian made vaccine will begin testing in humans from July.

The vaccine is called Covaxin and has been developed by Bharat Biotech in collaboration with India’s National Institute of Virology and the Indian Council of Medical Research.

India’s drug control authorities have allowed the company to conduct Phase 1 and 2 trials in humans after it submitted results showing safety and an efficacy immune response in animals. These two new trials are designed to test if the vaccine is safe in humans. The company said a local strain of COVID-19 was vital to creating this vaccine candidate.

Bharat Biotech has previously delivered more than 4 billion doses of various vaccines worldwide for diseases like H1N1 and rotavirus.

More than 16,000 people have died from the virus in India since January, and it reported 20,000 new infections on Monday. The country has recorded 548,318 total cases making it the world’s fourth worst affected country after the US, Brazil and Russia. This has led to lockdowns being implemented for a second time in the states of Assam and West Bengal, but some of its worst affected states like Maharashtra have eased their restrictions.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches